Lataa...
Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
BACKGROUND: The introduction of rituximab (R) to conventional CHOP chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) led to an unequivocal improvement in survival, establishing RCHOP as the standard of care. Still, nearly 40% of DLBCL patients will eventually die of relapsed dis...
Tallennettuna:
| Julkaisussa: | Ann Oncol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4288137/ https://ncbi.nlm.nih.gov/pubmed/24625454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu109 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|